Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ALZN NASDAQ:CMMB NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.90$1.92$1.26▼$4.50$16.20M2.4344,463 shs48,360 shsALZNAlzamend Neuro$1.21+4.3%$1.16$0.84▼$3.60$4.41M0.14324,874 shs71,588 shsCMMBChemomab Therapeutics$1.53-7.3%$1.79$1.35▼$4.84$11.88M0.64270,191 shs183,073 shsTPSTTempest Therapeutics$0.98-0.3%$1.42$0.94▼$12.23$15.72M-1.73179,966 shs171,466 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%+1.06%-0.52%+18.01%-34.03%ALZNAlzamend Neuro+4.31%+6.14%0.00%+18.63%-61.71%CMMBChemomab Therapeutics-7.27%-44.77%-7.27%-8.93%-67.31%TPSTTempest Therapeutics-0.31%-1.05%-22.18%-53.75%-85.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.90$1.92$1.26▼$4.50$16.20M2.4344,463 shs48,360 shsALZNAlzamend Neuro$1.21+4.3%$1.16$0.84▼$3.60$4.41M0.14324,874 shs71,588 shsCMMBChemomab Therapeutics$1.53-7.3%$1.79$1.35▼$4.84$11.88M0.64270,191 shs183,073 shsTPSTTempest Therapeutics$0.98-0.3%$1.42$0.94▼$12.23$15.72M-1.73179,966 shs171,466 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%+1.06%-0.52%+18.01%-34.03%ALZNAlzamend Neuro+4.31%+6.14%0.00%+18.63%-61.71%CMMBChemomab Therapeutics-7.27%-44.77%-7.27%-8.93%-67.31%TPSTTempest Therapeutics-0.31%-1.05%-22.18%-53.75%-85.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/AALZNAlzamend Neuro 2.00Hold$28.002,214.05% UpsideCMMBChemomab Therapeutics 2.00Hold$25.001,533.99% UpsideTPSTTempest Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ALZN, AIMD, CMMB, and TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026TPSTTempest Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/29/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/11/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/26/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/8/2026CMMBChemomab Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/6/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K134.90N/AN/A$1.29 per share1.47ALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/ACMMBChemomab TherapeuticsN/AN/AN/AN/A$2.00 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-160.55%-62.29%N/AALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)CMMBChemomab Therapeutics-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%8/13/2026 (Estimated)TPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)Latest ALZN, AIMD, CMMB, and TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026TPSTTempest Therapeutics-$0.30N/AN/AN/AN/AN/A7/28/2026Q4 2026ALZNAlzamend Neuro-$0.67N/AN/AN/AN/AN/A5/14/2026Q1 2026CMMBChemomab Therapeutics-$0.04-$0.22-$0.18$0.24N/AN/A5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/ACMMBChemomab TherapeuticsN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.580.550.50ALZNAlzamend NeuroN/A1.991.99CMMBChemomab TherapeuticsN/A10.3110.31TPSTTempest TherapeuticsN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALZNAlzamend Neuro49.61%CMMBChemomab Therapeutics46.05%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%ALZNAlzamend Neuro1.39%CMMBChemomab Therapeutics11.91%TPSTTempest Therapeutics36.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos408.52 million7.69 millionNot OptionableALZNAlzamend Neuro43.80 million3.75 millionNo DataCMMBChemomab Therapeutics207.20 million6.34 millionNot OptionableTPSTTempest Therapeutics2015.98 million10.18 millionNo DataALZN, AIMD, CMMB, and TPST HeadlinesRecent News About These CompaniesTempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 202620 minutes ago | globenewswire.comTempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | quiverquant.comQTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | globenewswire.comTempest Therapeutics Announces Resignation of Board DirectorMay 29, 2026 | tipranks.comTempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term WarrantsMay 29, 2026 | quiverquant.comQTempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsMay 29, 2026 | globenewswire.comTempest Therapeutics Announces Multiple Board Director ResignationsMay 22, 2026 | tipranks.comTempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | finanznachrichten.deTempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6, 2026 | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comNew Strong Buy Stocks for April 10thApril 10, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comTempest Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comTempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 SharesMarch 26, 2026 | insidertrades.comTempest Therapeutics Announces Up To $6 Million Private PlacementMarch 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 12, 2026 | finanznachrichten.deTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, AIMD, CMMB, and TPST Company DescriptionsAinos NASDAQ:AIMD$1.90 0.00 (0.00%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.85 -0.05 (-2.63%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Alzamend Neuro NASDAQ:ALZN$1.21 +0.05 (+4.31%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.14 -0.06 (-5.37%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Chemomab Therapeutics NASDAQ:CMMB$1.53 -0.12 (-7.27%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.57 +0.04 (+2.61%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Tempest Therapeutics NASDAQ:TPST$0.98 0.00 (-0.31%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.00 +0.02 (+1.58%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
